These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 15647208)

  • 21. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
    Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
    Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of mitogen-activated protein kinases in Thy-1-induced T-lymphocyte activation.
    Conrad DM; Furlong SJ; Doucette CD; Boudreau RT; Hoskin DW
    Cell Signal; 2009 Aug; 21(8):1298-307. PubMed ID: 19324083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacteria in Crohn's disease: mechanisms of inflammation and therapeutic implications.
    Balfour Sartor R
    J Clin Gastroenterol; 2007; 41 Suppl 1():S37-43. PubMed ID: 17438417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
    Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Indications and results of infliximab in Crohn's disease].
    Karoui S; Boubaker J; Filali A
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The frequency of sister chromatid exchanges in patients with Crohn's disease and the effect of therapy with "anti-tumor necrosis factor" on this frequency.
    Danalioglu A
    Hepatogastroenterology; 2009; 56(91-92):729-33. PubMed ID: 19621692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Both etanercept and infliximab can elevate tumor necrosis factor (TNF)-alpha and be the cause of treatment related new onset disease: the need to measure circulating TNF-alpha.
    Kast RE; Altschuler EL
    J Rheumatol; 2008 Aug; 35(8):1679; author reply 1679-80. PubMed ID: 18671327
    [No Abstract]   [Full Text] [Related]  

  • 28. Antibodies to tumor necrosis factor-alpha in the treatment of Crohn's disease.
    Brown SJ; Abreu MT
    Curr Opin Drug Discov Devel; 2005 Mar; 8(2):160-8. PubMed ID: 15782540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V; Pontikaki I; Gattinara M; Fantini F
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?
    Gaertner WB; Decanini A; Mellgren A; Lowry AC; Goldberg SM; Madoff RD; Spencer MP
    Dis Colon Rectum; 2007 Nov; 50(11):1754-60. PubMed ID: 17899271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
    Rutgeerts P; Diamond RH; Bala M; Olson A; Lichtenstein GR; Bao W; Patel K; Wolf DC; Safdi M; Colombel JF; Lashner B; Hanauer SB
    Gastrointest Endosc; 2006 Mar; 63(3):433-42; quiz 464. PubMed ID: 16500392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease.
    Saruta M; Yu QT; Fleshner PR; Mantel PY; Schmidt-Weber CB; Banham AH; Papadakis KA
    Clin Immunol; 2007 Dec; 125(3):281-90. PubMed ID: 17897887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of p38 MAP kinase in CD4+ lymphocytes by infliximab therapy in patients with rheumatoid arthritis.
    Garfield BE; Krahl T; Appel S; Cooper SM; Rincón M
    Clin Immunol; 2005 Aug; 116(2):101-7. PubMed ID: 15914087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The signalling profile of recombinant human orexin-2 receptor.
    Tang J; Chen J; Ramanjaneya M; Punn A; Conner AC; Randeva HS
    Cell Signal; 2008 Sep; 20(9):1651-61. PubMed ID: 18599270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
    Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter survey.
    Matsumoto T; Iida M; Motoya S; Haruma K; Suzuki Y; Kobayashi K; Ito H; Miyata M; Kusunoki M; Chiba T; Yamamoto S; Hibi T
    Dis Colon Rectum; 2008 Jun; 51(6):916-23. PubMed ID: 18322754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Why does tumor necrosis factor targeted therapy reactivate tuberculosis?
    Ehlers S
    J Rheumatol Suppl; 2005 Mar; 74():35-9. PubMed ID: 15742463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease.
    Pazianas M; Rhim AD; Weinberg AM; Su C; Lichtenstein GR
    Ann N Y Acad Sci; 2006 Apr; 1068():543-56. PubMed ID: 16831950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.